Tobacco Cessation Flashcards

1
Q

Nicotine: Pharmacodynamics

A
  • Rapidly absorbed
  • Acts on nicotine receptors in brain and CNS
  • Each puff maintains nicotine blood levels
  • Development of tolerance
  • Withdrawal syndrome if discontinued
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Goals of Treatment

A
  • Complete discontinuation of tobacco use
  • Nicotine replacement therapy
  • – Gradual, controlled reduction of nicotine to avoid withdrawal symptoms
  • Bupropion (Zyban)
  • – Tobacco-free by 7 to 12 weeks of therapy
  • Varenicline (Chantix)
  • – Tobacco-free by 12 weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Rational Drug Selection

A

Nicotine replacement therapy

Antidepressant
- Bupropion

Nicotine receptor partial agonist
- Varenicline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Nicotine Replacement Therapy

A
  • Used in patients who smoke more than 20 cigarettes per day
  • OTC
  • –Gun: Nicorette
  • –Patch: Nicotrol, Nicoderm, Habitrol
  • –Lozenges: Commit
  • Prescription drugs
  • –Nasal spray: Nicotrol NS
  • –Inhaler: Nicotrol
  • E-cigarettes not recommended
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Nicotine Replacement Therapy: Precautions and contraindications

A

Pregnancy

  • Gum: Category C
  • Transdermal patch: category D

Contraindicated

  • immediately after a MI
  • immediately after a stroke
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Nicotine Gum: Pharmacodynamics

A
  • Improves cessation success
  • Buccal absorption
  • Need to follow direction or nicotine will release too quickly, increasing ADRs
  • More than 25 cigarettes per day: use states at 4 mg every hour
  • Less than 25 cigarettes per day: used 2 mg every hour
  • Patients weaned off medication after 2 to 3 months of nicotine abstinence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Nicotine Lozenge: Pharmacodynamics

A
  • Lozenge slowly dissolves in mouth
  • Patient is advised not to chew lozenge
  • Dose is 1 lozenge every 1-2 hours
  • Patients should use 4 mg if smoking within 30 minutes of waking
  • Patient should not eat or drink while lozenge is in mouth
  • Wean after 6 weeks of nicotine abstinence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Nicotine Patch: Pharmacodynamics

A
  • Transdermal absorption
  • 16-hour and 24-hour patches
  • Slow onset, steady state once at peak
  • Dose of patch determined by number of cigarettes the patient smokes per day
  • Patch dose decreased gradually
  • Patient cannot smoke while using patch
  • ADRs: nicotine toxicity
  • Advice about disposing of patches safely
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Nicotine Nasal Spray: Pharmacodynamics & Patient Education

A

Intranasal administration

Rapid onset and peak

Patient Education

  • Proper administration
  • ADRs

Abuse potential

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Nicotine Inhaler: Pharmacodynamics & ADRs

A

Inhaled drug

Puffs on inhaler for 20 minutes

Dose titrated down gradually over 12 weeks

ADRs:

  • Cough
  • Mouth irritation
  • Dyspepsia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

E-CIgarettes: Pharmacodynamics

A

Battery-operated devices

Inhaled nicotine

Used by some to help with nicotine withdrawal when stopping smoking

Studies on safety needed because of potential toxic inhalants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Anti-depressants

A

Bupropion (Zyban)

Unknown action in smoking cessation

Started 1-2 weeks before quit date

  • Dose: 150 mg daily for 3 days
  • Then increased to 150 mg twice daily

Quit day

  • Cold turkey
  • Ok to use nicotine replacement product

Therapy continued for 7-12 weeks, may be longer, if needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bupropion (Zyban): Precautions & Contraindications

A
  • Seizure disorders, bulimia, and anorexia nervosa
  • Neurological disorders
  • Reduced dose in renal dysfunction
  • Avoid in pregnancy
  • Not prescribed with Wellbutrin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Bupropion (Zyban): ADRs

A

Insomnia (40%)

Dizziness (10%)

Dry mouth (10%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Nicotinic Receptor Partial Agonists: Pharmacodynamics & Dosing

A
  • Varenicline (Chantix)
  • Highly selective to the alpha-4-beta-2 and moderately selective to the 5-HT3 receptor
  • Started a week before quit date
  • Dosing: 0.5 mg orally daily for the first 3 days
  • –Then 0.5 mg twice daily on days 4-7
  • –On day 8, increased to 1.0 mg twice daily
  • Therapy continued for 12 weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Varenicline (Chantix): ADRs and Precautions

A

ADRs

  • Nausea: 16-41%
  • Neuropsychiatric symptoms
  • – Changes in behavior, agitation, depressed mood, suicidal ideation, and actual suicide behavior

Pregnancy category C: Should not be used in pregnancy

Adult use only (18 years or older)

17
Q

Alpha2 Adrenergic Agonists

A

Clonidine: Second-line treatment

Used for patients who refuse or cannot tolerate first-line therapy

Use of tablets or patch

18
Q

Combination Therapy

A

Agency for Health Care Policy and Research Smoking Cessation: Clinical Practice Guidelines

Level A evidence for:

  • Long-term (greater than 14 weeks) nicotine patch + other nicotine replacement therapy (gum and spray)
  • Nicotine patch + nicotine inhaler
  • Nicotine patch + bupropion - sustained-release
19
Q

Non-pharmacological Treatment of Nicotine Addiction

A
  1. Individual or group counseling
  2. Support via telephone hot line or internet support group
  3. Interventions: problem solving, skills, training, relapse prevention, and stress management
20
Q

Patient Variables

A

Pregnancy

  • Nicotine replacement products not recommended
  • Bupropion (Zyban) not recommended
  • Varenicline (Chantix) not recommended

Children- not used

Adolescents

  • Early identification and support for quitting
  • Some evidence for use of patch (prescription needed)
21
Q

Monitoring

A
  • Withdrawal symptoms
  • Nicotine toxicity
  • ADRs
  • Neuropsychiatric changes monitored in patients on varenicline
22
Q

Patient Education

A

Proper dosing

  • Removal of patch at appropriate time
  • Proper dosing of gum and inhaler

Advice on OTC products

Monitoring of ADRs